Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinous

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Mar 2017: Trial started, NCT03074513
  2. 8 Mar 2017: Trial registered, NCT03074513

The trials

NCT03074513: Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

State
Under way
Phase
Phase 2
People
133 taking part
Started
3 Mar 2017
Primary completion
30 Sep 2027
Arms
Treatment (atezolizumab, bevacizumab)
Results
None posted
  1. 3 Mar 2017: Trial started
  2. 8 Mar 2017: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.